4.6 Article

Novel signaling interactions between proteinase-activated receptor 2 and Toll-like receptors in vitro and in vivo

期刊

MUCOSAL IMMUNOLOGY
卷 3, 期 1, 页码 29-39

出版社

NATURE PUBLISHING GROUP
DOI: 10.1038/mi.2009.120

关键词

-

资金

  1. NIH [R37 AI-18797, R01 DK048373, R01 HL084387, R01 DK081376, R01 CA098369, R01 AI050632, T32 AI-07540, AI-18797]
  2. JRT [R01 AI50632S1]
  3. NATIONAL CANCER INSTITUTE [P30CA134274, R01CA098369] Funding Source: NIH RePORTER
  4. NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL084387] Funding Source: NIH RePORTER
  5. NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007540, R01AI018797, R01AI050632, R37AI018797, R56AI018797] Funding Source: NIH RePORTER
  6. NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK081376, R01DK048373] Funding Source: NIH RePORTER

向作者/读者索取更多资源

Toll-like receptors (TLRs) and proteinase-activated receptors (PARs) function as innate immune biosensors in mucosal epithelial cells (ECs). We previously reported the functional and physical interactions between TLR4 and PAR(2). We have extended these findings herein by showing the cooperation between PAR(2) and TLR2, TLR3, or TLR4 for activation of nuclear factor-kappa B-dependent signaling in mucosal EC lines. In contrast, activation of PAR(2) negatively regulated TLR3-dependent antiviral pathway, blunting the expression of TLR3/interferon regulatory factor-3 (IRF-3)-driven genes, as well as activation of IRF-3 and STAT1. Consistent with these in vitro observations, PAR(2)(-/-) and TLR4-/- mice, which were refractory to footpad edema induced by PAR(2) agonist peptide, were protected from mouse-adapted H1N1 influenza A virus-induced lethality when compared to wild-type (WT) mice. These data support and extend our recently described, novel model of PAR(2)-TLR4 receptor cooperativity and highlight the complexity of signaling integration between heterologous innate immune biosensors.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据